The Conversation (0)
The Irish Independent reports that AstraZeneca (NYSE:AZN, LSE:AZN) will buy biotech company Spirogen for up to $440 million to bolster its R&D in oncology.
The Irish Independent reports that AstraZeneca (NYSE:AZN, LSE:AZN) will buy biotech company Spirogen for up to $440 million to bolster its R&D in oncology.
As quoted in the market news:
Privately held Spirogen focuses on antibody-drug conjugate technology, which has the potential to directly target cancer tumours while safeguarding healthy cells, AstraZeneca said.
AstraZeneca said it would pay an initial $200m plus a further $240m if Spirogen meets development targets.
Click here for the full article in Irish Independent
Â